CONTEXT: Inverse associations between 25-OH vitamin D levels and cardiovascular morbidity and mortality have been reported. OBJECTIVES: Our goals were to 1) investigate effects of correcting inadequate D status on lipids, 2) determine whether free 25-OH D is better correlated with lipids than total 25-OH D. DESIGN: A randomized, double-blind placebo-controlled trial was performed. SETTING:Participants resided in the general community. PARTICIPANTS: Adults with inadequate D status were randomized to D3: 14 men, 12 women, age 60 ± 8 years (mean ± SD) orplacebo: 12 men, 11 women: 59 ±12 years. INTERVENTION: Responses to 12-week oral vitamin D3 titrated (1000-3000 IU/d) to achieve 25-OH D levels ≥25 ng/mL were compared to placebo. MAIN OUTCOME MEASURES: Measurements were 25-OH D (tandem mass spectometry), free 25-OH D (direct immunoassay), lipids (directly measured triglyceride, cholesterol, and subfractions; plant sterols and cholesterol synthesis precursors), and safety labs before and after 6 and 12 weeks D3 or placebo. Data were analyzed by repeated measures ANOVA and linear regression. RESULTS:Vitamin D3 was titrated to 1000 IU/d in 15/26 (58%), to 2000 IU/d in 10, and 3000 IU/d in one patient. D3 had no effect on cholesterol or cholesterol subfractions except for trends for decreases in atorvastatin-treated patients (cholesterol, P = .08; low-density lipoprotein [LDL] cholesterol, P = .05). Decreased campesterol concentrations (P = .05) were seen with D3 but not placebo in statin-treated patients. Relationships between total 25-OH D and lipids were not detected, but inverse linear relationships were detected between free 25-OH D and triglycerides (P = .03 for all participants [n = 49], P = .03 in all statin-treated [n = 19], and P = .0009 in atorvastatin-treated [n = 11]), and between free 25-OH D and LDL cholesterol (P = .08 overall, P = .02 in all statin-treated, and P = .03 for atorvastatin-treated), and total cholesterol (P = .09 overall; P = .04 for all statin-treated, and P = .05 for atorvastatin-treated). CONCLUSIONS: Vitamin D lipid-lowering effects appear limited to statin-treated patients and are likely due to decreased cholesterol absorption. Relationships between lipids and D metabolites were only detected when free 25-OH D was measured, suggesting the superiority of determining free 25-OH D levels compared to total 25-OH vitamin D levels when analyzing biologic responses.
RCT Entities:
CONTEXT: Inverse associations between 25-OH vitamin D levels and cardiovascular morbidity and mortality have been reported. OBJECTIVES: Our goals were to 1) investigate effects of correcting inadequate D status on lipids, 2) determine whether free 25-OH D is better correlated with lipids than total 25-OH D. DESIGN: A randomized, double-blind placebo-controlled trial was performed. SETTING:Participants resided in the general community. PARTICIPANTS: Adults with inadequate D status were randomized to D3: 14 men, 12 women, age 60 ± 8 years (mean ± SD) or placebo: 12 men, 11 women: 59 ±12 years. INTERVENTION: Responses to 12-week oral vitamin D3 titrated (1000-3000 IU/d) to achieve 25-OH D levels ≥25 ng/mL were compared to placebo. MAIN OUTCOME MEASURES: Measurements were 25-OH D (tandem mass spectometry), free 25-OH D (direct immunoassay), lipids (directly measured triglyceride, cholesterol, and subfractions; plant sterols and cholesterol synthesis precursors), and safety labs before and after 6 and 12 weeks D3 or placebo. Data were analyzed by repeated measures ANOVA and linear regression. RESULTS:Vitamin D3 was titrated to 1000 IU/d in 15/26 (58%), to 2000 IU/d in 10, and 3000 IU/d in one patient. D3 had no effect on cholesterol or cholesterol subfractions except for trends for decreases in atorvastatin-treated patients (cholesterol, P = .08; low-density lipoprotein [LDL] cholesterol, P = .05). Decreased campesterol concentrations (P = .05) were seen with D3 but not placebo in statin-treated patients. Relationships between total 25-OH D and lipids were not detected, but inverse linear relationships were detected between free 25-OH D and triglycerides (P = .03 for all participants [n = 49], P = .03 in all statin-treated [n = 19], and P = .0009 in atorvastatin-treated [n = 11]), and between free 25-OH D and LDL cholesterol (P = .08 overall, P = .02 in all statin-treated, and P = .03 for atorvastatin-treated), and total cholesterol (P = .09 overall; P = .04 for all statin-treated, and P = .05 for atorvastatin-treated). CONCLUSIONS:Vitamin Dlipid-lowering effects appear limited to statin-treated patients and are likely due to decreased cholesterol absorption. Relationships between lipids and D metabolites were only detected when free 25-OH D was measured, suggesting the superiority of determining free 25-OH D levels compared to total 25-OH vitamin D levels when analyzing biologic responses.
Authors: C E Teunissen; M Mulder; J de Vente; K von Bergmann; C De Bruijn; H W Steinbusch; D Lütjohann Journal: Neurochem Res Date: 2001-11 Impact factor: 3.996
Authors: Christopher M Adams; Julian Reitz; Jef K De Brabander; Jamison D Feramisco; Lu Li; Michael S Brown; Joseph L Goldstein Journal: J Biol Chem Date: 2004-09-27 Impact factor: 5.157
Authors: Dieter Lütjohann; Andreas Brzezinka; Esther Barth; Dorothee Abramowski; Matthias Staufenbiel; Klaus von Bergmann; Konrad Beyreuther; Gerd Multhaup; Thomas A Bayer Journal: J Lipid Res Date: 2002-07 Impact factor: 5.922
Authors: Michael F Holick; Rachael M Biancuzzo; Tai C Chen; Ellen K Klein; Azzie Young; Douglass Bibuld; Richard Reitz; Wael Salameh; Allen Ameri; Andrew D Tannenbaum Journal: J Clin Endocrinol Metab Date: 2007-12-18 Impact factor: 5.958
Authors: Ishir Bhan; Camille E Powe; Anders H Berg; Elizabeth Ankers; Julia B Wenger; S Ananth Karumanchi; Ravi I Thadhani Journal: Kidney Int Date: 2012-03-07 Impact factor: 10.612
Authors: Huicui Meng; Nirupa R Matthan; Edith Angellotti; Anastassios G Pittas; Alice H Lichtenstein Journal: Am J Clin Nutr Date: 2020-09-01 Impact factor: 7.045
Authors: Janice B Schwartz; J Christopher Gallagher; Rolf Jorde; Vivian Berg; Jennifer Walsh; Richard Eastell; Amy L Evans; Simon Bowles; Kim E Naylor; Kerry S Jones; Inez Schoenmakers; Michael Holick; Eric Orwoll; Carrie Nielson; Martin Kaufmann; Glenville Jones; Roger Bouillon; Jennifer Lai; Davide Verotta; Daniel Bikle Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: Rene F Chun; Albert Shieh; Carter Gottlieb; Vahe Yacoubian; Jeffrey Wang; Martin Hewison; John S Adams Journal: Front Endocrinol (Lausanne) Date: 2019-10-24 Impact factor: 6.055